Agilent Technologies to acquire Cartagenia, leading provider of software to enable clinical analysis of genomics data

Santa Clara, CA / BOSTON, MA : 4 May 2015 - Agilent Technologies Inc. (NYSE: A) and Cartagenia today announced that they have signed a definitive agreement under which Agilent will acquire Cartagenia, a leading provider of software and services for clinical genetics and molecular pathology labs.

Cartagenia, which has offices in Leuven, Belgium, and Boston, Massachusetts, provides software solutions for variant assessment and reporting of clinical genomics data from next-generation sequencing and microarrays. Uniquely geared to routine clinical labs, Cartagenia's solutions are FDA-registered as exempt Class I Medical Devices in the U.S. and as Class I Medical Devices in Europe. The Cartagenia Bench platform enables technicians, lab directors and clinicians to visualize, assess and report clinical genetics data in context of patient information.

More information on the press release.

Next > Avantium appoints Gabrielle Reijnen to its Supervisory Board

Previous > NGDATA Achieves Oracle Big Data Appliance Optimized Status